The company did not provide data, but said results for patients who received sotorasib at the 960mg dose were consistent with those seen in the Phase I portion of the Phase I/II study, which showed an overall response rate of 35.3%. ......
Sotorasib, a KRAS G12C inhibitor, showed an overall response rate and duration of response that analysts called approvable, but they noted the results have waned over time, and combinations may be the way forward.
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
An investigator in the Phase I/II trial of Amgen's AMG 510 said that while data for colorectal cancer indicated low activity as a single agent, it nevertheless represented a doubling in progression-free survival over what is seen from currently available treatments.
The company announced poster presentations for the ASCO virtual meeting on AMG 510, its KRAS G12c inhibitor, in patients with colorectal cancer and a broad range of cancers. But an analyst called the drug "unimpressive" outside of non-small cell lung cancer.
An analyst noted that Mirati's MRTX849, a KRAS G12C inhibitor, is six to nine months behind Amgen's AMG 510, but that the market has room for both. The data presented were on patients with lung and colorectal cancers.
The biotech company presented data for AMG 510 at the European Society for Medical Oncology during the weekend. Although the drug showed activity, the data got mixed reactions from investment bank analysts.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose.
The company said in its earnings statement that AMG 510 had produced objective responses in patients with colorectal and appendiceal cancers. The Phase II portion of the Phase I/II study, which may be used for registration, will start enrolling in the coming days.
The company is targeting pathways such as SHP2 and KRAS G12C. RAS mutations have been an attractive target in oncology due to the central role they play in cancers.
Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.
This webinar will explore how a banking platform approach could be the resource for your company.
The biotech company plans to present Phase I data at ASCO on the drug, AMG 510, which targets KRAS mutations in solid tumors.